CA
NZ
UK
AU
IND
US
The transaction involved approximately 619,965 common shares or pre-funded warrants, a relatively modest share count on its face. But the real story sits in what came attached to that raise: newly issued Series A-3 and Series A-4 warrants, each exercisable at $6.21 per share. …
On paper, this should have been an unambiguously positive day for the stock. Rating upgrades paired with substantial price target increases typically move shares higher, sometimes sharply, as institutional investors and algorithmic screens react to the bullish signal. A jump from $3 to $13 …
The $1.00 minimum bid price rule is one of Nasdaq's core continued-listing standards, designed to ensure that companies trading on the exchange maintain a share price reflecting a baseline level of market confidence and liquidity. Companies that fall below this threshold for an extended …
Q32 Bio (NASDAQ: QTTB) posted Phase 2a SIGNAL-AA Part B results for bempikibart in severe alopecia areata, showing a 35.3% mean reduction in SALT scores in the mITT population and a 40% SALT-20 response rate. With no new safety signals emerging, the company said …
The facts are straightforward: BL1107, also known as WB007, did not meet its primary endpoint in a Phase 2 glaucoma study. Rather than pursuing additional post-hoc analyses in search of a salvageable subgroup signal, or committing further resources to a program that failed its …
Key HighlightsForte Biosciences (NASDAQ: FBRX): Shares jumped 20% to $43.92 on statistically significant Phase 1b vitiligo data for FB102, with Guggenheim reiterating Buy and a $75 target.Virax Biolabs (NASDAQ: VRAX): Stock fell 36% to $4.08 despite a $3.3 million capital raise, due to a …
DNL628, also referred to as OTV:MAPT, targets tau, a protein that forms the neurofibrillary tangles long implicated in Alzheimer's disease progression, using an antisense oligonucleotide approach designed to reduce production of the tau protein at the genetic level. The program is currently in ongoing …
Severe alopecia areata remains a difficult-to-treat autoimmune condition in which the body's immune system attacks hair follicles, often leading to extensive and psychologically distressing hair loss. While JAK inhibitors from larger pharmaceutical companies have reshaped the treatment landscape in recent years, they carry boxed …
ROBBIN1 is a registration-directed study evaluating a neoadjuvant combination of BOT (botensilimab) and BAL (balstilimab) in patients with microsatellite-stable (MSS) colon cancer, a genetic subtype that has historically responded poorly to immunotherapy. Neoadjuvant treatment means the combination is given before surgery, with the goal …
Late-line metastatic cancer studies, by their nature, treat patients whose disease has progressed after multiple prior lines of therapy. These settings are notoriously difficult for demonstrating strong efficacy signals, both because the patient population is more heavily pretreated and because meaningful survival benefits are …
Please wait processing your request...